|
|
Volumn 360, Issue 17, 2009, Pages 1789-1792
|
|
More on reports of esophageal cancer with oral bisphosphonate use
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALENDRONIC ACID;
BISPHOSPHONIC ACID DERIVATIVE;
CLODRONIC ACID;
ETIDRONIC ACID;
IBANDRONIC ACID;
RISEDRONIC ACID;
BONE DENSITY CONSERVATION AGENT;
CALCITONIN;
RALOXIFENE;
AGE DISTRIBUTION;
CANCER INCIDENCE;
CANCER RISK;
DRUG SURVEILLANCE PROGRAM;
ESOPHAGUS CANCER;
FOLLOW UP;
FOOD AND DRUG ADMINISTRATION;
FRACTURE;
HUMAN;
LETTER;
PRIORITY JOURNAL;
SEX RATIO;
STATISTICAL ANALYSIS;
STOMACH CANCER;
TREATMENT DURATION;
CHEMICALLY INDUCED DISORDER;
CONFIDENCE INTERVAL;
ESOPHAGUS TUMOR;
NOTE;
ORAL DRUG ADMINISTRATION;
PROPORTIONAL HAZARDS MODEL;
RISK ASSESSMENT;
STOMACH TUMOR;
CANCER REGISTRY;
COMPARATIVE STUDY;
INCIDENCE;
OSTEOPOROSIS;
UNITED STATES;
RISK REDUCTION;
ADMINISTRATION, ORAL;
BONE DENSITY CONSERVATION AGENTS;
CONFIDENCE INTERVALS;
DIPHOSPHONATES;
ESOPHAGEAL NEOPLASMS;
FOLLOW-UP STUDIES;
FRACTURES, BONE;
HUMANS;
PROPORTIONAL HAZARDS MODELS;
RISK ASSESSMENT;
STOMACH NEOPLASMS;
CALCITONIN;
INCIDENCE;
OSTEOPOROSIS;
RALOXIFENE;
SEER PROGRAM;
UNITED STATES;
|
|
EID: 65949103196
PISSN: 00284793
EISSN: 15334406
Source Type: Journal
DOI: 10.1056/NEJMc096026 Document Type: Letter |
|
Times cited : (67)
|
|
References (1)
|
